• menu
    Market Place Market Place
    Sourcing support Sourcing Support
    API / FDF
    Excipients
    Services
    Developments
    News
    Market Intel
    #Phispers
    #SpeakPharma
    #LearnMore

    NEWS

    DRUGS & DEVELOPMENTS

    MARKET INTEL by PharmaCompass

    AMI Lifesciences is Driven by Chemistry. Powered by People.

    Novartis, BioArctic Partner To Penetrate the Blood-Brain Barrier

    BIOSPACE

    BioArctic: Interim Report for the period April - June 2025

    PR NEWSWIRE

    Lilly Answers Novartis Breast Cancer Rivalry with Survival Win

    FIERCE PHARMA

    Novartis pens BioArctic neuro pact worth $30M upfront

    FIERCE BIOTECH

    Novartis, BioArctic Partner on BrainTransporter for Neurology

    EXPRESSPHARMA

    Novartis ESC Data Showcases Cardiovascular Portfolio Strength

    GLOBENEWSWIRE

    Novartis Scores Double Phase 3 Win in Sjögren`s Syndrome

    FIERCE BIOTECH

    Novartis Weighs Deal for Biotech Avidity Biosciences

    REUTERS

    Novartis Hunts New Assets, Rumored Takeover of RNA Specialist

    BIOSPACE

    FDA Approves Novartis` Leqvio (Inclisiran) for First-Line Use

    PR NEWSWIRE

    Novartis India Reports Rs. 27.62 Cr Net Profit in Q1 FY26

    INDPHARMAPOST

    Novartis Drops up to $1B+ for Drug Discovery Deal With Matchpoint

    GLOBENEWSWIRE

    Analysis Group Explores HEOR Use in Rare Disease CGTs

    PR NEWSWIRE

    Novartis Speeds up Us Manufacturing of Key Drugs as Tariffs

    BIOSPACE

    Novartis` Pluvicto Picks up Speed, Delivers Another Trial Win

    FIERCE PHARMA

    Novartis boosts FY 2025 core income outlook on robust Q2 sales

    GLOBENEWSWIRE

    Novartis Names Mukul Mehta CFO as Harry Kirsch Retires

    GLOBENEWSWIRE

    Novartis Loses Bid to Block Us Entresto Generic Through 2026

    REUTERS

    US Entresto Generic Unblocked as Novartis Loses Bid till 2026

    REUTERS

    Novartis inks $175M option deal for Sironax’s blood-brain barrier

    PR NEWSWIRE

    Novartis` Malaria Drug for Babies Gets First Global Approval

    FIERCE PHARMA

    Novartis gets Approval for First malaria drug for babies

    REUTERS

    Novartis Drug Cosentyx Fails Late-Stage Trial for Artery Disease

    REUTERS

    Novartis Pens ProFound Pact for Cardiovascular Disease Targets

    FIERCE BIOTECH

    Novartis completes acquisition of Regulus Therapeutics

    GLOBENEWSWIRE

    Amneal, Kashiv Report Positive Data for Xolair Biosimilar

    GLOBENEWSWIRE

    Novartis HSR waiting period for Regulus Therapeutics offer ends

    GLOBENEWSWIRE

    Biogen, BMS and Novartis bag spots on Cannes Lions shortlists

    FIERCE PHARMA

    Novartis Fabhalta® improves hemoglobin in new PNH patients

    GLOBENEWSWIRE

    Novartis Asks Court for Swift Decision in Entresto Patent Case

    FIERCE PHARMA

    Novartis` Pluvicto to Slow Prostate Cancer in Earlier Setting

    REUTERS

    Novartis Pluvicto Shows rPFS Benefit In PSMA+ Prostate Cancer

    GLOBENEWSWIRE

    Novartis Kisqali Cut Recurrence Risk in Young Early Breast Cancer

    GLOBENEWSWIRE

    Novartis expands collaboration with Shanghai Pharma in China

    FIERCE PHARMA

    5 People Accused of Insider Trading Tied to Novartis Buy

    FIERCE BIOTECH

    Novartis starts tender offer for Regulus Therapeutics

    GLOBENEWSWIRE

    Apotex Launches Generic Tasigna Capsules in Us with Exclusivity

    PR NEWSWIRE

    Novartis Offers Payment Plan for High-Cost Heart Medicine

    ECONOMICTIMES

    Novartis data at ASCO and EHA highlights Momentum of Portfolio

    GLOBENEWSWIRE

    Abu Dhabi, Novartis Ink Deal for Disease Prevention

    BIOSPECTRUM

    Erasca looks to partner off late-stage melanoma asset

    FIERCE BIOTECH

    Novartis to keep making malaria drugs if orders dry up amid cuts

    REUTERS

    PTC and Novartis’ Huntington`s data fail to convince investors

    FIERCE BIOTECH

    Incyte, Novartis reach settlement in Jakafi royalty dispute

    FIERCE PHARMA

    BioNTech says Novartis executive Zapata to become CFO

    REUTERS

    Novartis to buy Regulus in up to $1.7 Billion deal

    REUTERS

    Novartis axes osteoarthritis asset and radioligand therapy

    FIERCE BIOTECH

    Novartis builds momentum with new drug launches

    FIERCE PHARMA

    Novartis raises 2025 forecast on strong Q1 momentum

    REUTERS

    Novartis sees double-digit sales growth, margin expansion in Q1

    GLOBENEWSWIRE

    Novartis & Sanofi CEOs say EU should raise drug prices of tariffs

    REUTERS

    Novartis terminates Ph 2 osteoarthritis trial testing

    FIERCE BIOTECH

    Novartis unveils $23B investment to beef up US manufacturing

    PR NEWSWIRE

    Blackstone & Anthos Announce Novartis has Completed Acquisition

    BUSINESSWIRE

    Novartis receives FDA accelerated approval for Vanrafia

    PR NEWSWIRE

    Grove AI Adds Former Executives to Advisory Board

    GLOBENEWSWIRE

    Market volatility halts Novartis` India arm stake sale

    #N/A

    Novartis appoints Karen Hale as Chief Legal Officer; Klaus Moosma

    GLOBENEWSWIRE

    FDA approve Novartis therapy Pluvicto for earlier use in Prostate Cancer

    GLOBENEWSWIRE

    Novartis to present new data at AAN on Kesimpta® safety in MS.

    GLOBENEWSWIRE

    Copyright © 2025 LePro PharmaCompass OPC Private Limited, All rights reserved.